Many neuropsychiatric drugs interact with more than one molecular target, and therapeutic indices might be improved by prospectively designing compounds with profiles optimized against a combination of targets. The dibenzo-epine scaffold is considered a privileged structure, and this scaffold has been explored rigorously in the search for potential novel neuropharmacologic treatments. Members of this chemical class are known to interact with many receptors and transporters, particularly those of the biogenic amine class. In this study, four points of diversity within a dibenzo-epine scaffold were varied systematically and the pharmacologic profiles of the compounds were assessed across 14 receptors and transporters thought to be important to clinical profiles of efficacy and safety. The resulting data were analyzed using a modified forward selection linear regression procedure, thus revealing potential pharmacophoric relationships of the assessed targets within this chemical class. The results highlight a strong covariance across numerous targets. Moreover, the outcome quantifies the innately problematic issue of prospectively designing compounds with defined affinities across multiple targets. Finally, an exploration of the correspondence of binding affinities to in vitro functional activity reveals an additional layer of complexity central to prospectively designing compounds to engage multiple targets. The apparent relatedness of the 5-HT 2a and D 2 activities suggests that the structural pharmacophores of these receptors overlap more closely with each other than with members of their respective families.
Introduction
The initial discoveries of imipramine and clozapine, the foundational neuropsychiatric drugs with tricyclic structures, spawned decades of research aimed at designing novel therapies for psychiatric disorders (Hippius, 1989) . Consequently, dibenzo-epine scaffolds were rigorously explored in search of novel neuropharmacologic drugs. Indeed, many new chemotherapeutics were brought to the marketplace based on the dibenzo-epine scaffold and hence, it is considered to be a privileged structure. The advent of receptor pharmacology revealed that members of this privileged structure can interact with a wide variety of targets, and that they can inhibit biogenic amine receptors and transporters, in particular (Coward, 1992) . Recently, there has been renewed appreciation for neuropsychiatric agents that engage multiple mechanisms. In fact, it has been hypothesized that complex neuropsychiatric disorders may only be optimally treated by drugs that engage multiple nodes within networked systems (Roth et al., 2004) .
A fundamental challenge in designing individual small molecules that selectively engage multiple targets in a network is the concurrent need to avoid engaging undesired targets. The single agent, multi-target approach presupposes that the pharmacophoric requirements of the desired targets are distinct enough from those of undesired targets that adequate separation of the corresponding affinities can be achieved (Xie et al., 2012) . The vast and varied clinical success realized with members of the dibenzo-epine scaffold implies that this class of compounds is well suited to exploring the pharmacophoric interdependencies of a subset of key receptors and transporters. A collection of twenty-four compounds from this class, systematically varied across four points of differentiation, were evaluated at fourteen receptors and transporters. The set contained five approved neuropsychiatric drugs and several active drug metabolites. The attendant pharmacophoric relationships of the test set were evaluated using a straightforward statistical method. The results quantify the covariate nature of the receptor affinities within the compound subset, producing models that explain considerable variance and reveal unexpected relationships.
Materials and methods

Compounds
Compounds 1 (CAS#5747-48-8), 2 (1977-09-9), 3 (5747-63-7), 4 (2058-52-8), 5 (858670-47-0), 6 (5747-55-7), 7 (21636-40-8), 8 (2058-53-9), 9 (14028-44-5), 10 (27833-64-3), 11 (179418-95-2), 12 (3527-47-7), 13 (56296-18-5), 14 (1977-07-7), 15 (858669-84-8), 16 (1977-08-8), 17 (6104-71-8), 18 (5786-21-0), 19 (5001-00-3), 20 (1977-11-3), 21 (138246-83-0), 22 (1977-12-4), 23 (858670-48-1) , and 24 (5542-88-1) were synthesized at AstraZeneca Pharmaceuticals, LP (Wilmington, DE) or Adesis, Inc. (New Castle, DE). All chemical structures were verified, and each has a purity of >95%.
Radioligand binding
Radioligand binding was performed on membranes prepared from stably transfected cells expressing human recombinant receptors or transporters. Radioligand binding at dopamine (catalog #220320, DAT), norepineprine (#204410, NET), and serotonin (#274030, SET) transporters was evaluated according to standard validated protocols under conditions defined by the contractor (Ricerca Biosciences, Concord, OH, USA; http://www.ricerca.com). Compounds were evaluated in duplicate across eight, half-log concentrations (0.3e300 mM). Radioligand binding at adrenergic a 1a (catalog #FAST-005B), serotonin 5-HT 1a (#FAST-0500B), serotonin 5-HT 2a (#FAST-0505B), serotonin 5-HT 2b (#FAST-0506B), serotonin 5-HT 2c (#FAST-507B), dopamine D 1 (#FAST-0100B), dopamine D 2 (#FAST-0101B), dopamine D 3 (#ES-0173B), histamine H 1 (#FAST-0170B), muscarinic M 1 (#FAST-0260B) and M 3 (#ES-212B) receptors was evaluated according to standard validated protocols under conditions defined by the contractor (Euroscreen, Gosselies, Belgium; http://www. euroscreen.com). Compounds were first evaluated at 0.1 nM, 10 nM, and 1 mM to establish approximate IC 50 values. Compounds were then evaluated in duplicate across ten concentrations bracketing the approximate IC 50 . Reference standards were run as an integral part of all assays to verify results.
In vitro functional assessment
In vitro functional assessment was performed on preparations of stably transfected cells expressing human recombinant receptors or transporters. Uptake inhibition at dopamine (catalog #316000), norepineprine (#302000), and serotonin (#364000) transporters was evaluated according to standard validated protocols under conditions defined by the contractor (Ricerca Biosciences, Concord, OH, USA; http://www.ricerca.com). Compounds were evaluated in duplicate across five concentrations (3, 30, & 300 nM, and 3 & 30 mM). Compounds were tested at adrenergic a 1a (catalog #FAST-005A), serotonin 5-HT 1a (#FAST-0500A), serotonin 5-HT 2a (#FAST-0505A), serotonin 5-HT 2b (#FAST-0506A), serotonin 5-HT 2c (#FAST-507A), dopamine D 2 (#FAST-0101A), histamine H 1 (#FAST-0170A), muscarinic M 1 (#FAST-0260A) and M 3 (#ES-212A) receptors in an aequorin assay format and at dopamine D 3 (ES-0173G) in a GTPgS assay format according to standard validated protocols under conditions defined by the contractor (Euroscreen, Gosselies, Belgium; http://www.euroscreen.com). Compounds were first evaluated in duplicate at 0.1 nM, 10 nM, and 1 mM for agonist activity and 0.05 nM, 5 nM, and 500 nM for antagonist activity to establish approximate EC 50 or IC 50 values. Compounds were tested at dopamine D 1 (#FAST-0100C) in a cAMP format. Compounds were first evaluated in duplicate at 0.1 nM, 10 nM, and 1 mM for agonist activity and antagonist activity to establish approximate EC 50 or IC 50 values. Compounds were then evaluated in duplicate across ten concentrations bracketing the approximate IC 50 . Measurable agonist activity was detected in very few instances. Compounds 1, 2, 3, 5, 7, 9, 11, 17, & 18 were also evaluated for agonist activity at 5-HT 1a in a GTPgS format, and compounds 1, 2, 5, 7, 11, 17, & 18 were also evaluated for agonist activity at M 1 in a FLIPR assay format (n ¼ 2 to 17 for each value, see supplemental methods). Reference standards were run as an integral part of all assays to verify results.
Calculation
For radioligand binding
For radioligand binding, all data were normalized to the control responses and non-linear regression curves fitted to them using logistic fits in GraphPad Prism 4.0 software (LaJolla, CA). The best curve fit of three parameter (i.e., nH ¼ 1) or four parameter models (i.e., variable nH) was determined by comparison using the F-test. For fits that did not converge, a two parameter model was attempted (i.e., bottom constrained to 0); 13 of 336 (or 3.8%) radioligand binding pK i values were determined with two parameter fits. Fits with pK i SEMs in excess 0.5 were rejected. The upper limit value (i.e., pK i < 5.0) is reported for data not meeting the described criteria (4 of 336). An estimated pK i of 3.5 was used as a value for the four unfitted sets (i.e., compound 13 at D 1 , D 2 , M 1 , & M 3 ) in subsequent correlation analyses.
For functional inhibition data
For functional inhibition data (i.e., antagonism), the best curve fit of three parameter (i.e., nH ¼ 1) or four parameter models (i.e., variable nH) was determined by comparison using the F-test. For fits that did not converge, fits with pIC 50 SEMs in excess of 0.5, or fits with less than 80% inhibition, the maximal inhibition at a specified concentration is reported. Only calculated pIC 50 s were used in correlation analysis. For functional activation data (i.e., agonism), a three parameter fit was attempted. For fits that did not converge, fits with pEC 50 SEMs greater than 0.5, maximal activation at a specified concentration is reported. Upper limit pEC 50 s are reported for M 1 FLIPR results.
Forward selection analyses
Forward selection analyses were developed using SigmaPlot for Windows v11 (Systat Software, Inc., San Jose, CA). A global ANOVA was performed with all sets of receptor pK i s to establish statistical validity of subsequent multiple comparisons. Next, each dependent variable (i.e., pK i at Receptor Y) was regressed across all independent variables (i.e., pK i s at Receptors X 1 , X 2 , . X k , X j ,. X n ). Following univariate analysis, a modified Forward Selection procedure similar to that described by Blanchet et al., was then used to build models of explained variance (Blanchet et al., 2008) . The independent variable with the highest significant correlation in univariate regression (e.g., Receptor Y vs. Receptor X k ) was assigned as the primary variable. The data were regressed again using the identified independent variable (i.e., Receptor X k ) as the primary variable and all remaining variables as secondary independent variables (i.e., pK i s at Receptors X 1 , X 2 , . X j , X l , . X n ). The second independent variable with highest significant correlation (e.g., Receptor Y vs. Receptor X k and Receptor X j ) was identified and the procedure was repeated until no additional significant model improvement was realized. As described by Blanchet et al., stopping criteria for model improvement includes both alpha significance and an improvement in the adjusted coefficient for multiple determination (R 2 adj ). Each final model was then evaluated using leave-one-out cross-validation (LOOCV), a cross-validation method reported to exhibit minimal bias with small data sets (Molinaro et al., 2005) . Mean-squared errors (MSE) were all below 0.01. All p-values were below 0.005 with the singular exception of the H 1 model missing compound 13 (p > 0.3), implying that the H 1 model may not be robust.
Results
The collection of 24 compounds contains five registered drugs, including three antipsychotics [i.e., clothiapine (4), clozapine (18), and loxapine (10)], an antidepressant (amoxapine, 9), and a hypnotic (perlapine, 20) . The subset also contains three known drug metabolites [i.e., norclozapine (17), norperlapine (19), and norquetiapine (1)]. All of the compounds have been described in patent applications, although the synthesis of compound 21 has never been reported. Surprisingly, no peer-reviewed biological data have been reported with compounds 5, 13, 15, 21, or 23 (Burki et al., 1977 (Burki et al., , 1978 Grimm et al., 2006; Kalhapure et al., 2011; Schmutz, 1975; Smits et al., 2006; Warawa et al., 2001) .
All 24 compounds were evaluated for inhibition of radioligand binding across 11 GPCRs and three biogenic amine transporters (see Table 1 ). pK i s could be calculated from the raw data for 332 of the 336 tests. Binding affinities expressed as pK i s range from 3.4 to 9.9 across all targets, with the average affinity at H 1 being the highest and the average affinity at DAT being the lowest. Compound 13 is the least potent across all targets.
All 24 compounds were also evaluated for antagonist activity across 11 GPCRs and for uptake inhibition at three biogenic amine transporters (Table 2) . Half maximal inhibitory concentrations (IC 50 ) could be calculated from the raw data for 281 of the 336 tests. Negative log IC 50 s (pIC 50 s) range from 4.3 to 10.2 across all targets, with the average affinity at 5-HT 2a being the highest and average affinity at DAT being the lowest. Compound 13 is the least potent across all targets. The relationships between binding affinities and inhibitory concentrations were evaluated across the fourteen targets using both parametric linear regression and non-parametric rank order (i.e., Spearman correlation) tests (Table 3) . The relationship between binding affinities and inhibitory concentrations was identified as both linear and monotonic for thirteen of the fourteen targets. Only the non-parametric test for DAT failed to achieve significance, perhaps due to the generally poor potency and the limited number of calculated inhibitory concentrations. From the analyses, it can be inferred that binding affinities are a suitable surrogate for functional inhibition within this chemical class and across the targets examined.
To investigate the correlative relationships across the given targets, simple linear regression comparisons were performed serially across all permutations using the radioligand binding affinity data (Table 4) . Approximately two-thirds of all comparisons are significant (i.e., p < 0.05), and more than 40% were strongly significant (p < 0.01) suggesting that the affinities at the targets examined are widely interrelated. Many of the covariate relationships might be expected based on known pharmacologic relationships (e.g., 82% correlation between the muscarinic family members, M 1 and M 3 ). However, strong correlations exist which span receptor families (e.g., 80% correlation between D 1 and 5-HT 2a ).
To ascertain the extent of binding affinity variance at each target that could be explained by the affinity at all other targets, a modified forward selection procedure was employed (Blanchet) . The procedure produces models which explain between 41% and 96% of the variance at each target. In most cases, two independent variables account for most of the explained variance.
All 24 compounds were also evaluated for agonist activity across the 11 GPCRs (Table 6 ). Only eight instances of measurable agonism were detected across the 264 evaluations. The findings from the initial agonist screen do not agree completely with previous reports (Jensen et al., 2008; Sur et al., 2003) . A subset of the compounds were evaluated for agonism at 5-HT 1a and M 1 in alternative formats. The data resulting from evaluation in the alternative assay formats is similar to those already reported.
Discussion
The identification of small molecules as potential therapeutics with exquisite selectivity for a single target has become a routine mode of operation in the field of drug discovery. However, challenges to this paradigm and arguments for multifunctional therapeutics have recently emerged (Hopkins, 2008) . Multifunctional agents have been known and used the field of neuropharmacology for many years. In this study, a collection of twenty-four compounds, many known to exhibit multifunctional properties, were selected and evaluated for binding affinity and functional response across a set of fourteen targets. Many of the members of the Table 2 Functional inhibition of all test compounds. Half-maximal inhibitory concentrations at test receptors are expressed as inverse log transforms (pIC 50 's). In instances where IC 50 's cannot be calculated, the maximum inhibition is expressed as a percentage in parenthesis. The concentrations at maximum inhibition are denoted as * ¼ 5 mM, # ¼ 15.8 mM, and y ¼ 30 mM (for transporters) or 31.6 mM (GPCRs). (Schmutz, 1975) . The collection examined here includes five approved neuropsychiatric drugs. Surprisingly, there is an equal number of compounds in the collection for which no biological data have been published in peerreviewed studies. The comprehensive evaluation of the defined subset of compounds from the privileged chemical space reported here highlights a fundamental issue in prospectively designing multifunctional molecules; concurrently designing away from undesired pharmacologic interactions is non-trivial. A modified forward selection linear regression was used to quantify the explained variance of binding affinities at individual targets as a function of binding affinities at all other targets (Table 5 ). It can be inferred from the models developed by the described procedure that the pharmacophoric requirements of certain targets overlap considerably. One particularly interesting (Cravchik and Goldman, 2000) . It is not known whether the observed 5-HT 2a /D 2 correlation will generalize to more chemotypes. Radioligand binding affinities (pK i s) correlated well with antagonist half maximal inhibitory concentrations (pIC 50 s), suggesting that the explained variance models developed using binding affinities might also be expected to correspond to functional antagonism. No attempt was made to correlate functional agonism, but the paucity of agonist activity at the eleven receptors screened suggests that agonism is less well predicted by binding affinity. In a few instances, the functional agonism detected did not correspond fully with published reports (Heusler et al., 2011; Jensen et al., 2008; Sur et al., 2003) . Discrepancies could represent differential sensitivity to receptor activation in the different assays.
Conclusion
The relatedness of the pharmacophores of a set of common psychiatric targets was mapped with a straightforward, but novel procedure using data generated with a collection of twenty-four compounds from a privileged tricycle structure. The modified forward selection analysis emphasizes the highly correlative nature of relative affinities across a number of targets within the chemical space studied, and provides a means to quantify these relationships. A fundamental challenge to the concept of prospectively designing multifunctional molecules is the ability to achieve specified affinity criteria at more than one target while avoiding unwanted interactions. If the principle outcome of the analysis reported here can be applied broadly, it suggests that meeting the challenge of designing multifunctional molecules may be a very low probability event when the design criteria are both rigid and numerous. As the generation of in vitro data continues to become increasingly facile, large and homogenous data sets should emerge. The modified forward selection procedure employed here may offer a useful method for analyzing those large and homogenous data sets.
